Serotonin inhibits trigeminal nucleus activity evoked by craniovascular stimulation through a 5HT(1B/1D) receptor: A central action in migraine?

Annals of Neurology

Volumn 43, Issue 6, 1998, Pages 711-718

  Goadsby, Peter J ^a,b   Hoskin, Karen L ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLAMINOSULFONYLMETHYL 3 (1 METHYL 2 PYRROLIDINYLMETHYL) 1H INDOLE; CHLORALOSE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; SEROTONIN; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SUMATRIPTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAT; CONTROLLED STUDY; MIGRAINE; NERVE CELL EXCITABILITY; NEUROMODULATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SUPERIOR SAGITTAL SINUS; TRIGEMINAL NUCLEUS;

ANIMALS; CATS; ELECTRIC STIMULATION; ELECTROPHYSIOLOGY; MEMBRANE POTENTIALS; MIGRAINE DISORDERS; NEURAL INHIBITION; OXADIAZOLES; PIPERAZINES; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN ANTAGONISTS; TRIGEMINAL NUCLEUS, SPINAL;

EID: 0031866735     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410430605     Document Type: Article

References (88)

1. Goadsby PJ, Hoskin KL. Is the action of serotonin in migraine due in part to inhibition of neurons in the trigeminal nucleus? Cephalalgia 1997;17:400 (Abstract)
2. Kimball RW, Friedman AP, Vallejo E. Effect of serotonin in migraine patients. Neurology (Minneapolis) 1960;10:107-111
3. Anthony M, Hinterberger H, Lance JW. Plasma serotonin in migraine and stress. Arch Neurol 1967;16:544-552
4. Ferrari MD. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325:316-321
5. Goadsby PJ, Zagami AS, Donnan GA, et al. A double blind placebo controlled crossover study of sumatriptan in the treatment of acute migraine attacks. Lancet 1991;2:782-783
6. Humphrey PPA, Goadsby PJ. Controversies in headache: the mode of action of sumatriptan is vascular? A debate. Cephalalgia 1994;14:401-410
7. Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157-203
8. Hartig PR, Hoyer D, Humphrey PPA, Martin GR. Alignment of receptor nomenclature with the human genome: classification of 5HT-1B and 5-HT1D receptor subtypes. Trends Pharmacol Sci 1996;17:103-105
9. Sicuteri F. Vasoneuroactive substances and their implications in vascular pain. Res Clin Stud Headache 1967;1:6-45
10. Curran DA, Hinterberger H, Lance JW. Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects. Brain 1965;88: 997-1010
11. Feniuk W, Humphrey PPA, Perren MJ. The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetised dogs. Br J Pharmacol 1989;96:83-90
12. Gupta P, Brown D, Butler P, et al. The in vivo pharmacological profile of a 5-HT1 receptor agonist, CP122,288, a selective inhibitor of neurogenic inflammation. Br J Pharmacol 1995; 116:2385-2390
13. Lee WS, Moskowitz MA. Conformationally restricted sumatriptan analogues, CP-122,288 and CP-122,638, exhibit enhanced potency against neurogenic inflammation in dura mater. Brain Res 1993;626:303-305
14. Roon K, Diener HC, Ellis P, et al. CP-122,288 blocks neurogenic inflammation but is not effective in aborting migraine attacks: results of two controlled clinical studies. Cephalalgia 1997;17:245
15. 1D antagonists. J Med Chem 1994;37:2253-2257
16. 1D binding sites. Eur J Pharmacol 1989;163:133-136
17. 1Dα receptor sites. Neuropharmacology 1995;34:235-237
18. 1D-like receptor. Cephalalgia 1996;16: 386
19. Connor HE, Feniuk W, Beattie DT, et al. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia 1997;17:145-152
20. 1B/1D) receptors. Br J Pharmacol 1997;122: 918-922.
21. Cumberbatch MJ, Hill RG, Hargreaves RJ. Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol 1997;328:37-40
22. 1D receptor agonist 311C90. Headache 1994;34:299-300
23. Goadsby PJ, Hoskin KL. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)-1-D receptor agonist zolmitriptan (311C90): are brain stem sites a therapeutic target in migraine? Pain 1996;67:355-359
24. Winner P, Ricalde O, Force BL, et al. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996;53:180-184
25. 1b binding sites in rat brain membranes: evidence for guanine nucleotide regulation of agonist affinity states. J Pharmacol Exp Ther 1987;243:989-1001
26. Hoskin KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine: a c-Fos and electrophysiology study. Brain 1996;119:249-256
27. 3H]-dihydroergotamine binding sites in the cat central nervous system: relevance to migraine. Ann Neurol 1991;29:91-94
28. Siegel S. Non-parametric statistics for the behavioural sciences. Tokyo: Kogakusha, 1956
29. Feindel W, Penfield W, McNaughton F. The tentotial nerves and localisation of intracranial pain in man. Neurology 1960; 10:555-563
30. McNaughton FL, Feindel WH. Innervation of intracranial structures: a reappraisal. In: Rose FC, ed. Physiological aspects of clinical neurology. Oxford: Blackwell Scientific Publications, 1977:279-293
31. Wolff HG. Headache and other head pain. New York: Oxford University Press, 1963
32. Kimmel DL. The nerves of the cranial dura mater and their significance in dural headache and referred pain. Clin Med Sch Q 1961;22:16-26
33. Penfield W, McNaughton FL. Durai headache and the innervation of the dura mater. Arch Neurol Psychiatry 1940;44: 43-75
34. Keller JT, Saunders MC, Beduk A, Jollis JG. Innervation of the posterior fossa dura of the cat. Brain Res Bull 1985;14:97-102
35. Keller JT, Marfurt CF. Peptidergic and serotoninergic innervation of the rat dura mater. J Comp Neurol 1991;309:515-534
36. Penfield W. A contribution to the mechanism of intracranial pain. Proc Assoc Res Nerv Ment Dis 1934;15:399-415
37. Steiger HJ, Tew JM, Keller JT. The sensory representation of the dura mater in the trigeminal ganglion of the cat. Neurosci Lett 1982;31:231-236
38. Ray BS, Wolff HG. Experimental studies on headache: pain sensitive structures of the head and their significance in headache. Arch Surg 1940;41:813-856
39. Martins IP, Baeta E, Paiva T, et al. Headaches during intracranial endovascular procedures: a possible model of vascular headache. Headache 1993;33:227-233
40. Liu-Chen LY, Mayberg MR, Moskowitz MA. Immunohistochemical evidence for a substance P-containing trigeminovascular pathway to pial arteries in cats. Brain Res 1983;268:162-166
41. Zagami AS, Goadsby PJ, Edvinsson L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 1990;16:69-75
42. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28:183-187
43. Gallai V, Sarchielli P, Floridi A, et al. Vasoactive peptides levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 1995;15:384-390
44. Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Brain 1994;117:427-434
45. Fanciullacci M, Alessandri M, Figini M, et al. Increases in plasma calcitonin gene-related peptide from extracetebral circulation during nitroglycerin-induced cluster headache attack. Pain 1995;60:119-123
46. Feniuk W, Humphrey PPA, Perren MJ, et al. Rationale for the use of 5-HT1-like agonists in the treatment of migraine. J Neurol 1991;238:S57-S61
47. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterising cerebrovascular and neuropeptide changes seen in man and cat. Ann Neurol 1993;33:48-56
48. Buzzi MG, Moskowitz MA, Shimizu T, Heath HH. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 1991;30:1193-1200
49. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992;13:307-311
50. O'Shaughnessy CT, Connor HE, Feniuk W. Extracellular recordings of membrane potential from guinea-pig isolated trigeminal ganglion: lack of effect of sumatriptan. Cephalalgia 1993;13:175-179
51. Verheyen A, Vlaminck E, Lauwers F, et al. Radioactive colloidal gold as a tool to quantify extravasation of macromolecules in the rat cremaster muscle. Int J Microcirc Clin Exp 1987;5: 321-333
52. 2A receptor antagonists: aryl aminoguanidines. Life Sci 1996;59:1259-1268
53. Hoskin KL, Goadsby PJ. CP122,288 has no effect on c-fos expression in the trigeminal nucleus caudalis after superior sagittal sinus stimulation. Cephalalgia 1997;17:402
54. 1Dβ. Proc Natl Acad Sci USA 1992; 89:3630-3634
55. Rebeck GW, Maynard KI, Hyman BT, Moskowitz MA. Selective 5HT1D alpha serotonin receptor gene expression in trigeminal ganglion: implications for antimigraine drug development. Proc Natl Acad Sci USA 1994;91:2666-2669
56. Bouchelet I, Cohen Z, Case B, Hamel E. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol 1996;50:219-223
57. 1D binding sites. Br J Pharmacol 1991;102:227-233
58. Schoeffter P, Hoyer D. How selective is GR43175? Interactions with functional 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol 1989;340: 135-138
59. 1D subtype. Br J Pharmacol 1991;102:191-197
60. 1D receptors involved? Naunyn Schmiedebergs Arch Pharmacol 1992;345:509-515
61. 1D-like receptors, and a comparison with grafted veins. Naunyn Schmiedebergs Arch Pharmacol 1992;345:500-508
62. 1D receptor subtype is negatively coupled to adenylate cyclase in calf substantia nigra. Naunyn Schmiedebergs Arch Pharmacol 1988;337:602-608
63. 1D recognition sites: radioligand binding studies in human, pig and calf brain membranes. Naunyn Schmiedebergs Arch Pharmacol 1988;337:595-601
64. 1D antagonist properties. Cephalalgia 1997;17:404
65. 3H]-sumatriptan binding in cat brain stem and spinal cord. Eur J Pharmacol 1995;280:175-178
66. 3H]sumatriptan labels both 5-HT1D and 5HT-1F receptor bindings sites in the guinea pig brain: an autoradiographic study. Naunyn Schmiedebergs Arch Pharmacol 1995;352:263-275
67. 3H] Sumatriptan binding sites in human brain: regional-dependent labelling of 5HT1D and 5HT1F receptors. Eur J Pharmacol 1996;295:271-274
68. Goadsby PJ, Knight YE. Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. Cephalalgia 1997;17:153-158
69. Kaube H, Hoskin KL, Goadsby PJ. Sumatriptan inhibits central trigeminal neurons only after blood-brain barrier disruption. Br J Pharmacol 1993;109:788-792
70. Shepheard SL, Williamson DJ, Williams J, et al. Comparison of the effects of Sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in the dura mater and c-fos mRNA expression in the trigeminal nucleus caudalis of rats. Neuropharmacology 1995;34:255-261
71. Knyihar-Csillik E, Tajti J, Samsam M, et al. Effect of a serotonin agonist (sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine model. J Neurosci Res 1997;48:449-464
72. Anthony M, Hinterberger H, Lance JW. The possible relationship of serotonin to the migraine syndrome. In: Friedman AP, ed. Research and clinical studies in headache, vol 2. Basel: Karger, 1969:29-59
73. Doenicke A, Brand J, Perrin VL. Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine. Lancet 1988;1:1309-1311
74. Wang W, Timsit-Berthier M, Schoenen J. Intensity dependence of the auditory cortical evoked potentials is pronounced in migraine: an indication of cortical potentiation and low serotonergic transmission? Neurology 1996;46:1404-1409
75. Schoenen J, Proletti-Cecchini P, Afra J. Evidence in man for a central effect of a 5-HT-1D-agonist, 311C90, from a study of the intensity dependence of the cortical evoked potential. Eur J Neurol 1996;3(Suppl 5):88
76. Edvinsson L, Degueurce A, Duverger D, et al. Central serotonergic nerves project to the pial vessels of the brain. Nature 1983;306:55-57
77. Cohen Z, Bonvento G, Lacombe P, Hamel E. Serotonin in the regulation of brain microcirculation. Prog Neurobiol 1996;50: 335-362
78. 131I-sodium tracers in the rat. Behav Brain Res 1995;72:189-196
79. 3H]-imipramine indicates the presence of a specific serotonin transport system on endothelial cells of porcine brain. Neurosci Lett 1995;194:21-24
80. Winkler T, Sharma HS, Stalberg E, et al. Impairment of blood-brain barrier function by serotonin induces desynchronization of spontaneous cerebral cortical activity: experimental observations in the anaesthetized rat. Neuroscience 1995;68:1097-1104
81. Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Neurology 1994;44: 1587-1592
82. Harper AM, MacKenzie ET, McCulloch J, Pickard JD. Migraine and the blood-brain barrier. Lancet 1977;1:1034-1036
83. Alvarez-Cermeno J, Gobernado JM, Aimeno A. Transient blood-brain barrier (BBB) damage in migraine. Headache 1986; 26:437
84. Nissila M, Parkkola R, Sonninen P, Salonen R. Incracerebral arteries and gadolinium enhancement in migraine without aura. Cephalalgia 1996;16:363
85. Visser WH, Vriend RHMD, Jaspers NMWH, Ferrari MD. Sumatriptan in clinical practice. Neurology 1996;47:46-51
86. Aube M. Treatment of slow-developing migraine with subcutaneous sumatriptan. Cephalalgia 1995;15 (Suppl 14):231
87. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nature Med 1995;1: 658-660
88. Harik SI, McGunigal T. The protective influence of the locus ceruleus on the blood-brain barrier. Ann Neurol 1984;15:568-574